N/A N=55 Robotic Bronchoscopy for Peripheral Pulmonary Lesions
Lung; Node
Primary: Number of Participants With Device or Procedure Related Adverse Events — 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=49 FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates
Pulmonary Infiltrate New
Primary: Number of Patients With Positive Culture or Molecular Results After Brochoscopy — 40 participants
N/A N=30 InvestigatioN of a Smart Probe for Lung lEsion Characterization Using Impedance Technology
Lung Cancer
Primary: The Ability of BioSpy System to Acquire Electrophysiological Measurements in the Relevant Tissues During Bronchoscopic Biopsy. — 26 Participants
N/A N=86 ENB-GS-TBLB for the Diagnosis of PPLs
Lung Cancer
Primary: The Difference of Diagnostic Value of ENB-GS-TBLB as Compared to GS-TBLB — 34; 25; 5; 16 participants — p=0.019
Phase 2 N=25 Percutaneous Image Guided Video-Assisted Thoracic Surgery (VATS) Resection of Lung Lesions
Lung Cancer
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 1 Participants
N/A N=60 Evaluation of the Incidence of Cerebral Lesions Post Pulmonary Vein Ablation Catheter (PVAC)
Atrial Fibrillation
Primary: New Asymptomatic Cerebral Embolic Lesions, Visualized as 'Bright Spots' on Post-ablation MRI. — 1 participants
Early Phase 1 N=17 Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung
Healthy · Latent Tuberculosis Infection (LTBI)
Primary: Median Difference in CD4 Cell Response to Intrabronchial Instillation of Tuberculin Purified Protein Derivative (PPD) — 5.26; 0.725; 29.9; 2.92 % Antigen Specific T…
N/A N=59 Mini Invasive Endomicroscopy of the Pleura for Malignancies Diagnosis
Pleural Diseases · Pleural Neoplasms
Primary: Malignant Pleural Infiltration Identification — 12; 27; 9; 4 Participants — p=0.023
Phase 2 N=171 Imaging Regional Lung Defect Severity
COPD
Primary: Gas Trapping Measured During Washout of the Perfluorinated Gas Mixture. — 0.718; 0.541; 0.308; 0.451 percentage of total lung volume — p=<0.0001
N/A N=24 Pilot Study of Navigational Bronchoscopy and Transthoracic Needle Biopsy
Peripheral Pulmonary Nodules
Primary: Feasibility — 24 participants
N/A N=258 Navigation Endoscopy to Reach Indeterminate Lung Nodules Versus Trans-Thoracic Needle Aspiration
Lung Nodule
Primary: Diagnostic Accuracy — 94; 81 Participants — p=0.003
N/A N=411 Robotic Versus Electromagnetic Bronchoscopy for Pulmonary LesIon AssessmeNT: (the RELIANT Trial)
Peripheral Pulmonary Lesions
Primary: Diagnostic Yield — 157; 158 Participants
N/A N=65 Probe Based Confocal Laser Endomicroscopy During Thoracoscopy for Pleural Malignancies Diagnosis.
Pleural Carcinomatosis
Primary: Pleural Carcinomatosis Identification (Compared to Standard Biopsies). Qualitative Criteria. — 8; 24; 21; 0 Participants — p=0.0003
Phase 2 N=62 Non-Invasive Diagnosis of Pulmonary Vascular Disease Using Inhaled 129Xe Magnetic Resonance Imaging
Pulmonary Vascular Disease
Primary: Participants Determined to be True Positives for Pulmonary Arterial Hypertension — 10; 15; 10; 5 Participants
N/A N=30 Feasibility of Performing Peripheral Pulmonary Lesion Biopsy Using Robotic Bronchoscopy-Guided Cryoprobe
Bronchi--Diseases · Lung Diseases, Obstructive · Lesions Mass
Primary: Ability to Successfully Obtain Sample — 123; 130 tissue samples
N/A N=21 Lung Ultrasound in PD Patients
Peritoneal Dialysis · Hypervolemia · VEGF Overexpression
Primary: Association Between Number of Kerley B Lines by Ultrasound and Serum VEGF-C Level (pg/ml) by Enzyme-linked Immunosorbent Assay — 0.29; 0.25; 0.33 ng/ml — p=0.039
N/A N=105 Piloting a Virtual Navigation (VN) System for Bronchoscopic Lung Nodule Sampling
Lung Cancer
Primary: Safety Measurement — 0; 0; 0; 0 Adverse events
N/A N=10 CrYobiopsy With Radial UltraSound Guidance
Pulmonary Disease
Primary: Time to Achieve Hemostasis After Obtaining Cryobiopsy — 146.55; 132.25 seconds — p=0.7878
Phase 2 N=10 Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)
Idiopathic Pulmonary Fibrosis
Primary: Primary Outcome — -0.0147; 0.0740 Unitless
N/A N=25 Assessment of Lung Movement With Computed Tomography (CT)
Interstitial Lung Disease
Primary: Lung Motion as Assessed by CT — 4.07; 5.56; 1.82; 2.46 Liters
N/A N=50 Pulmonary Artery Repair With Covered Stents
Pulmonary Stenosis · Pulmonary Regurgitation · Tetralogy of Fallot
Primary: Successful Repair of Conduit Disruption — 48 participants
N/A N=139 Non-Contrast 4DCT to Detect Pulmonary Thromboembolic Events
Pulmonary Thromboembolisms · Pulmonary Embolism
Primary: Correlation of 4DCT Identified Perfusion With SPECT/CT Identified Perfusion — 0.45 Spearman correlation
N/A N=50 The Right Ventricular Pulmonary Circulation Continuum in Mitral Valve Disease Study
Mitral Regurgitation · Pulmonary Hypertension
Primary: Impaired Post-operative Functional Capacity — 35 Participants
N/A N=25 Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients
Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — -6.2; -15.3 meters
Early Phase 1 N=22 Quantifying Airway Inflammation With Radiologic Tests
Lung Inflammation
Primary: Change in Ki (Measure of [18F]Fluorodeoxyglucose ([18F]FDG) Uptake Determined by Patlak Graphical Analysis) in the Right Lung 24 Hours After LPS Instillation — 18.8…
Phase 3 N=38 Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Resection
Pulmonary Surgical Procedures
Primary: Predicted Percentage of Remaining Pulmonary Function — 73.4; 71.9 percentage of remaining function
N/A N=30 Clinical Description of a Bronchoscopic Approach to Ablate Lung Nodules Using the Emprint™ Ablation Catheter
Cancer, Lung · Cancer, Metastatic to Lung
Primary: Number of Participants With AEs Related to the Emprint™ Ablation Catheter Kit With Thermosphere™ Technology — 1 Participants
N/A N=420 A Multi-Center Trial of the ProLung Test™
Solitary Pulmonary Nodule · Multiple Pulmonary Nodules
Primary: Clinical Efficacy in the Risk Stratification of Patients With Indeterminate Lesions — 70.37; 46.97; 68.47; 49.21 percentage
Phase 2 N=21 11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension
Pulmonary Hypertension
Primary: Changes in RV Function — 7.56 percentage
N/A N=25 EPIONE Guided Lung Evaluation
Lung Cancer
Primary: Feasibility of the Device — 26 Number of targets reached